

Projeto de Pesquisa:

Efeito da estimulação transcraniana por corrente contínua (ETCC) na assimetria da marcha em pessoas com doença de Parkinson

Informações Preliminares**Responsável Principal**

CPF/Documento: 406.032.948-71	Nome: Vinicius Cavassano Zampier
Telefone: 1733428268	E-mail: zampiervc@gmail.com

Instituição Proponente

CNPJ: 48.031.918/0028-44	Nome da Instituição: UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO
--------------------------	---

É um estudo internacional? Não

Assistentes

CPF/Documento	Nome
223.676.818-48	Fabio Augusto Barbieri

Área de Estudo**Grandes Áreas do Conhecimento**

- Grande Área 4. Ciências da Saúde

Propósito Principal do Estudo

- Clínico

Título Público da Pesquisa: Efeito da estimulação transcraniana por corrente contínua (ETCC) na assimetria da marcha em pessoas com doença de Parkinson**Contato Público**

CPF/Documento	Nome	Telefone	E-mail
406.032.948-71	Vinicius Cavassano Zampier	1733428268	zampiervc@gmail.com

Contato Científico: Vinicius Cavassano Zampier

Desenho de Estudo / Apoio Financeiro

Desenho do Estudo: Intervenção/Experimental

Condições de saúde ou problemas

Condição de saúde ou Problema

Doença de Parkinson

Descritores Gerais para as Condições de Saúde

CID1-10:Classificação Internacional de Doenças

Código CID	Descrição CID
G20	Doença de Parkinson

DeCS:Descritores em Ciência da Saúde

Código DECS	Descrição DECS
D010300	Doença de parkinson

Descritores Específicos para as Condições de

CID1-10:Classificação Internacional de Doenças

Código CID	Descrição CID
G20	Doença de Parkinson

DeCS:Descritores em Ciência da Saúde

Código DECS	Descrição DECS
D010300	Doença de parkinson

Tipo de Intervenção: Experimental

Natureza da Intervenção

- Dispositivo

Descritores da Intervenção

Descritores da Intervenção

Intervenções

Estimulação transcraniana por corrente contínua

Lista de CID

Código CID	Descrição CID
G20	Doença de Parkinson

Lista de DECS

Código DECS	Descrição DECS
D010300	Doença de parkinson

Fase

- Fase 1

Haverá uso de placebo ou a existência de grupos que não serão submetidos em nenhuma intervenção:

Será necessário a implementação de um grupo placebo para testar a eficácia da estimulação transcraniana por corrente contínua na assimetria da marcha de pessoas com doença de Parkinson

Haverá aplicação de washout:

Será necessário a aplicação de um período washout de uma semana para verificar qual protocolo de estimulação transcraniana por corrente contínua apresenta melhores resultados

Desenho:

Ensaio clínico randomizado duplo cego sham-controlado.

Apoio Financeiro

CNPJ	Nome	E-mail	Telefone	Tipo
				Financiamento Próprio

Palavra Chave

Palavra-chave

Controle motor

Marcha

Assimetria

Data de Submissão do Projeto: 14/04/2026

Nome do Arquivo: PB_INFORMAÇÕES_BÁSICAS_DO_PROJETO_2780599.pdf

Versão do Projeto: 1

Detalhamento do Estudo

Resumo:

Gait disorders, such as asymmetries in spatiotemporal parameters, are considered one of the leading causes of disability in individuals with Parkinson's disease (PD). Initially, gait asymmetry can be attributed to unilateral motor degeneration, and its progression is associated with changes in motor cortex activity. Individuals with PD exhibit increased motor cortex activity as a compensatory strategy to cope with motor deficits and maintain gait control. In this context, therapies that directly modulate cortical activity, such as transcranial direct current stimulation (tDCS), may contribute to reducing gait asymmetry. This study aims to investigate, through two randomized clinical trials, the effects of single and multiple tDCS sessions on gait asymmetry in individuals with PD. In the first study, the effects of three tDCS protocols, applied for 20 minutes at an intensity of 2 mA, will be compared: (1) unilaterally over the motor cortex contralateral to the most affected side, (2) unilaterally over the motor cortex ipsilateral to the most affected side, and (3) bilaterally over the motor cortex. The protocol order will be randomized for each participant, with a one-week interval between sessions. In the second study, the effects of multiple tDCS sessions on gait asymmetry will be evaluated, using the most promising protocol identified in Study 1. The intervention will last four weeks, with 20-minute sessions at 2 mA conducted on non-consecutive days (48-hour intervals). The findings from these studies will provide a solid theoretical foundation for understanding the effects of a non-pharmacological therapy on gait asymmetry in individuals with PD, contributing to the development of more effective clinical strategies.

Introdução:

Parkinson's disease (PD) is typically characterized as a brain disorder that causes involuntary or uncontrollable movements, such as difficulty with balance and coordination. The literature consistently shows that individuals with PD exhibit reduced gait velocity and step length, as well as increased gait variability. In addition, gait asymmetry (GA) defined as differences in the bilateral behavior of the steps or legs during walking is believed to result from the disease and the imbalanced strength of muscles, a typical symptom of PD. Indeed, GA exacerbates gait impairments, leading to an increased risk of falls; approximately 70% of individuals with PD fall annually, and 13% fall more than once a week. GA is a relevant clinical concern that should be addressed during the rehabilitation of movement disorders. Understanding the effects of PD on GA could improve mobility and reduce the incidence of falls, highlighting the importance of therapeutic interventions aimed at minimizing GA in individuals with PD. Under normal conditions, the ability to perform steady and symmetric gait does not rely heavily on cognitive resources. However, when gait is impaired (e.g., as in PD), GA appears to depend more on attentional and cognitive input. This is particularly evident in individuals with PD during dual-task conditions, in which increased GA and greater impairment in gait parameters are commonly observed. GA is typically assessed through spatiotemporal gait parameters (e.g., step length, swing time, or stance time), while muscle-based evaluations of GA remain relatively underexplored. Many individuals with PD demonstrate greater spatiotemporal GA (e.g., step length, step time, and swing time) than age-matched healthy controls. Moreover, environmental factors also influence GA in PD; for instance, individuals with PD display greater asymmetry in step length and duration when encountering obstacles, compared to neurologically healthy controls. Clinical evidence supports the pathogenic role of asymmetry in disrupting the rhythmic right/left antiphase activation of the lower limbs during gait in PD. The asymmetric degeneration of dopaminergic neurons in the substantia nigra, particularly within the basal ganglia, is the most apparent explanation for motor asymmetry in PD. This imbalance in dopaminergic signaling alters the cortico, basal ganglia, thalamus, cortical circuits, contributing to deficits in motor coordination and gait. Consequently, therapeutic interventions that modulate neural activation appear to be a promising approach to reduce GA in PD, as they may enhance neural functioning, trigger plasticity processes, and improve spatiotemporal gait parameters. Nevertheless, the effects of neural modulation on brain areas involved in gait control such as the motor and prefrontal cortices on GA, whether in spatiotemporal parameters or muscle activity during walking, have not yet been thoroughly investigated, particularly with regard to the prescription of effective therapeutic interventions to mitigate GA in PD. In recent years, non-invasive brain stimulation (NIBS) techniques have been increasingly employed to address a range of pathological conditions. Among these, transcranial direct current stimulation (tDCS) stands out as a safe and user-friendly technique and has become one of the most frequently used in research settings. Activity in the ventro-posterolateral thalamic nucleus increases in response to tDCS, suggesting potential modulation of basal ganglia function and improvements in motor control. Prior studies have reported positive effects of tDCS on motor performance in both individuals with PD and neurologically healthy older adults. For example, a single 20-minute tDCS session over the motor cortex increased gait speed in healthy older adults. In individuals with PD, eight 20-minute tDCS sessions targeting the motor cortex improved balance control by reducing the time needed to recover balance following a perturbation. However, the effects of tDCS applied unilaterally targeting either the more or less affected hemisphere or bilaterally on GA in individuals with PD remain poorly understood. Neurophysiological studies have revealed asymmetries in M1 excitability [33, 34] and reduced transcallosal inhibition in the more affected hemisphere compared to the less affected one [35, 36]. These findings may reflect the asymmetric dysfunction of the striato frontal motor circuit and are believed to contribute to the characteristic motor asymmetry in PD. Since a reduction in GA (e.g., step length asymmetry) indicates improved motor control, it is essential to clarify the efficacy of therapeutic interventions, such as tDCS, which can modulate neural excitability in brain regions involved in the basal ganglia thalamus cortical circuits. Investigating both acute and long-term effects of tDCS on GA in PD is crucial to optimizing therapeutic strategies, particularly during the early stages of the disease. Consequently, evaluating changes in GA may serve as a valuable metric for assessing intervention outcomes and refining gait rehabilitation approaches in PD. To further our understanding of tDCS effects on GA in individuals with PD and to establish an optimal stimulation protocol, it is essential to explore both the immediate and long-term impacts of this technique. Furthermore, identifying a protocol capable of inducing early neuroplastic changes and maintaining these effects over time is critical for maximizing therapeutic outcomes. Therefore, this study aims to address the current knowledge gaps by experimentally investigating: (i) the immediate effects of tDCS on GA and the influence of different tDCS target areas on GA, and (ii) the long-term effects of repeated tDCS sessions on GA in individuals with PD.

Hipótese:

i) An acute term of tDCS applied over the M1 and DLPFC of the most affected brain hemisphere would reduce the asymmetry in spatial-temporal gait parameters such as step length, velocity, time width and double support phase in people with PD; Considering that anodal tDCS over the most affected brain hemisphere significantly improved the motor performance of both hands when compared to the application in the least affected brain hemisphere in people with PD, we expect that one session of acute tDCS over the M1 and DLPFC of the most affected brain hemisphere will lead to an accentuated reduction on GA in PD compared to applied tDCS on the least affected brain hemisphere or bilateral stimulation over the M1 and DLPFC; ii) long-term anodal tDCS would reduce the asymmetry in spatial-temporal gait parameters such as step length, velocity, time width and double support phase in people with PD and its effect will persist at least 1-month follow-up the last session.

Objetivo Primário:

The main aim of this project is to investigate the effects of a single tDCS session on different stimulation targets, as well as the

effects of multiple tDCS sessions on GA in individuals with PD, through two separate studies

Objetivo Secundário:

i) determine whether the acute term of tDCS applied over the M1 and dorsolateral prefrontal cortex (DLPFC) of most affected brain hemisphere can improve GA in people with PD, and compare the effect of tDCS on the least affected brain hemisphere vs. the most affected brain hemisphere vs. bilateral stimulation over the M1 and DLPFC on GA in people with PD; ii) to examine the effects of long-term anodal tDCS on GA in people with PD.

Metodologia Proposta:

Participants Individuals with idiopathic PD will be recruited from specialized centers in the Bauru region and diagnosed according to the UK Parkinson's Disease Brain Bank criteria. All procedures will comply with the Declaration of Helsinki, and all participants will provide written informed consent before enrollment. Study Design Two randomized, double-blind, sham-controlled clinical trials will be conducted to investigate the acute and long-term effects of transcranial direct current stimulation (tDCS) on gait asymmetry in people with PD. Study 1 will use a crossover design in which each participant receives both active and sham tDCS combined with three stimulation setups, whereas Study 2 will use a parallel-group design with repeated sessions of active or sham tDCS. Study 1 $\hat{c}$ Acute tDCS Effects In Study 1, participants will complete six tDCS sessions (three active and three sham) in randomized and counterbalanced order. In each condition (active or sham), stimulation will be applied in three weekly sessions targeting: (1) the primary motor cortex/dorsolateral prefrontal cortex (M1/DLPFC) of the most affected hemisphere (C3 or C4), (2) the M1/DLPFC of the less affected hemisphere, and (3) bilateral M1/DLPFC, with at least one week between sessions to avoid carry-over effects. Active tDCS will be delivered at 2 mA for 20 minutes using saline-soaked sponge electrodes (25 cm²), with the anode over C3/C4 (unilateral or bilateral) and the cathode(s) over the contralateral (or bilateral) supraorbital area; sham stimulation will mimic ramp-up and ramp-down but will be switched off after approximately 10 seconds. Study 2 $\hat{c}$ Long-term tDCS Effects Study 2 will investigate the long-term effects of the most effective montage identified in Study 1 using a randomized, double-blind, parallel-group design. Participants will be allocated to active or sham tDCS and will receive 12 sessions over four weeks (three sessions per week with 48-hour intervals), at 2 mA for 20 minutes in the active group and for 10 seconds in the sham group, with identical electrode placement and ramp procedures. Gait and EMG Assessment In both studies, clinical characterization will include the Hoehn and Yahr scale, the motor section of the Unified Parkinson's Disease Rating Scale, and the Montreal Cognitive Assessment. Gait will be assessed before and 15 $\hat{c}$ 20 minutes after each tDCS session in Study 1, and at pre-intervention, post-intervention, and one-month follow-up in Study 2. Participants will perform multiple trials of barefoot overground walking on an 8 $\times$ 3 m walkway at preferred speed, while three-dimensional kinematics are recorded with a 10-camera motion capture system and reflective markers on the feet and C7. Surface electromyography (EMG) of tibialis anterior, gastrocnemius medialis, vastus lateralis, and biceps femoris of both legs will be recorded using a wireless system synchronized with foot switches to define gait phases. Spatiotemporal parameters (step length, velocity, width, duration, and double support) and EMG root mean square values will be calculated for each limb, and gait asymmetry indices will be derived using a symmetry index comparing most and less affected sides. Data Analysis and Safety Normality of the variables will be checked, and appropriate parametric or non-parametric tests will be applied. In Study 1, acute effects will be analyzed using repeated-measures models including stimulation condition (active vs sham), time (pre vs post), and setup (most affected, less affected, bilateral). In Study 2, mixed models with repeated measures will compare groups (active vs sham) across time (pre, post, follow-up) for gait and EMG asymmetry outcomes, with significance set at $\hat{c}$ = 0.05 and effect sizes reported. Adverse events (e.g., tingling, itching, headache) will be systematically monitored at each session, and any serious event will lead to interruption of stimulation and referral to medical evaluation.

Critério de Inclusão:

Age above 50 years, Hoehn and Yahr stage up to 3, ability to walk independently, stable antiparkinsonian medication.

Critério de Exclusão:

Exclusion criteria include history of brain surgery or other neurological or musculoskeletal disorders affecting gait and any metallic implant over the head.

Riscos:

Participation in this study involves minimal risks that are mainly associated with transcranial direct current stimulation (tDCS) and repeated gait assessments. tDCS is a non $\hat{c}$ invasive brain stimulation technique that uses low-intensity direct current (2 mA) applied through saline $\hat{c}$ soaked sponge electrodes positioned on the scalp. Previous studies have shown that tDCS is generally safe when applied within these parameters; however, participants may experience mild, transient adverse effects such as tingling, itching, burning sensation or redness under the electrodes, as well as occasional headache or fatigue during or shortly after stimulation. These symptoms usually resolve spontaneously within minutes and will be systematically monitored at each session; if discomfort becomes intolerable, stimulation will be immediately interrupted and the participant will be evaluated by the research team. The gait assessment procedures require participants to walk repeatedly along an 8 $\times$ 3 m walkway at their preferred speed while barefoot, with reflective markers and surface electromyography electrodes attached to the skin. These procedures may cause mild musculoskeletal fatigue or discomfort due to repeated trials and may induce transient imbalance, particularly in individuals with Parkinson's disease, who already present gait and postural control impairments. To minimize these risks, assessments will be conducted in a controlled laboratory environment, participants will be continuously supervised by trained researchers, and a member of the team will walk alongside the participant to provide physical assistance if needed. Trials will be stopped immediately if the participant reports excessive fatigue, dizziness, pain, or any other symptom of discomfort. There are no known serious or long $\hat{c}$ term adverse effects associated with the tDCS parameters used in this protocol in individuals with Parkinson's disease; nonetheless, any unexpected or serious adverse event will lead to immediate discontinuation of the intervention, notification of the responsible neurologist, and referral for appropriate clinical care. Confidentiality risks will be minimized by coding all data and storing personal information separately from research records in password $\hat{c}$ protected files accessible only to the research team. Participants will be informed that they can withdraw from the study at any time, without any penalty or impact on their usual clinical care.

Benefícios:

Participation in this study may provide both direct and indirect benefits to individuals with Parkinson's disease and to the broader scientific and clinical community. At the individual level, the tDCS intervention may lead to improvements in spatiotemporal gait symmetry (e.g., step length, step timing, double support), which are closely related to functional mobility and risk of falls in people with PD. By targeting motor and prefrontal cortical regions involved in gait control, tDCS may enhance neural excitability and promote neuroplastic adaptations that translate into more stable and efficient walking patterns. These changes could contribute to increased safety during daily activities, greater independence, and better perceived quality of life, although such benefits cannot be guaranteed for any given participant. At the scientific and societal levels, this project is expected to generate novel evidence regarding the acute and long $\hat{c}$ term effects of different tDCS montages on gait asymmetry in PD, a symptom that is highly prevalent and functionally disabling yet poorly explored in the context of non $\hat{c}$ invasive brain stimulation. The results will help identify the most effective stimulation targets (most affected hemisphere, least affected hemisphere, or bilateral stimulation) and optimize stimulation parameters for future clinical use. In addition, this study will contribute to the development of non $\hat{c}$ pharmacological, low $\hat{c}$ cost therapeutic strategies that can complement conventional pharmacological and surgical treatments, potentially expanding

rehabilitation options for individuals with PD. The findings may also support the inclusion of tDCS-based approaches within multidisciplinary assistive technology programs at the host institution and collaborating centers.

Metodologia de Análise de Dados:

EMG Gait variables data will be recorded from Noraxon electromyograph device and a camera system VICON and will be processed in MatLab environment. All analyses will be performed using standard statistical software (e.g., SPSS, R), with the significance level set at $\alpha = 0.05$. Continuous variables will be inspected for data entry errors, outliers, normality (e.g., Shapiro-Wilk test) and homogeneity of variances; when necessary, data will be transformed or analyzed with non parametric tests. Descriptive statistics (mean, standard deviation, confidence intervals) will be calculated for all gait, electromyography (EMG) and clinical variables.

For each participant, spatiotemporal gait parameters (step length, step time, gait speed, step width, double support phase) and EMG amplitude (root mean square) of the tibialis anterior, gastrocnemius medialis, vastus lateralis and biceps femoris will be calculated separately for the most affected and less affected sides. Gait asymmetry indices will be derived using a symmetry index that compares the values of the most affected and less affected limbs for each parameter.

Study 1 - Acute effects

In Study 1, the acute effects of tDCS will be evaluated using repeated measures analyses that account for stimulation condition (active vs sham), stimulation target (most affected hemisphere, less affected hemisphere, bilateral) and time (pre vs post). For normally distributed variables, repeated measures ANOVA with appropriate within subject factors will be applied to gait and asymmetry outcomes; when assumptions are violated, equivalent non parametric tests (e.g., Friedman test with post hoc Wilcoxon signed rank tests) will be used. Significant interactions (e.g., condition $\times$ time, condition $\times$ target $\times$ time) will be followed by planned pairwise comparisons with adjustment for multiple testing (e.g., Bonferroni correction). Effect sizes (e.g., partial eta squared or rank based measures) will be reported to quantify the magnitude of tDCS effects on gait asymmetry.

Study 2 - Long term effects

In Study 2, group (active vs sham) and time (baseline, post intervention, one month follow up) effects on gait and EMG asymmetry indices will be examined using mixed ANOVA with one between subject factor (group) and one within subject factor (time), when parametric assumptions are met. If assumptions are not satisfied, non parametric alternatives for repeated measures (e.g., Mann-Whitney tests on change scores, Friedman tests within groups) will be applied. For significant group $\times$ time interactions, post hoc tests with multiple comparison correction will identify at which time points active tDCS differs from sham and whether improvements are maintained at follow up.

Exploratory analyses and missing data

Exploratory correlation analyses may be performed between gait asymmetry indices and clinical measures (e.g., Hoehn and Yahr stage, UPDRS motor scores, cognitive performance) to investigate associations between changes in gait and disease severity. Missing data will be documented; if the amount is small and random, analyses will use available cases, whereas systematic missingness will be examined and handled according to best statistical practice (e.g., sensitivity analyses).

Desfecho Primário:

The primary outcomes will be symmetry indices computed for spatiotemporal gait parameters (step length, step time, gait speed, step width and double support phase) comparing the most affected and less affected limbs. For each parameter, a symmetry index will be calculated using established formulas (e.g., Herzog et al.) so that a value of zero indicates perfect symmetry and positive or negative values indicate the magnitude and direction of asymmetry. In addition, symmetry indices for EMG variables (root mean square amplitude and co-activation ratios of tibialis anterior, gastrocnemius medialis and vastus lateralis, biceps femoris) will be computed across gait phases for both legs. These indices will be used to test the main hypotheses that (i) a single tDCS session (Study 1) and (ii) multiple tDCS sessions (Study 2) reduce gait asymmetry in people with Parkinson's disease, and that these effects differ according to stimulation target and are maintained at one-month follow-up in the long-term protocol.

Desfecho Secundário:

Mean values of spatiotemporal parameters (gait speed, step length, step time, step width, double support duration) for the most affected and less affected limbs, independently of asymmetry indices, will be treated as secondary outcomes to characterize overall gait performance and potential tDCS-induced improvements. In the sample size calculations for both studies, gait speed is used as the reference variable for detecting group and condition differences over time.

Electromyographic activity and co-activation:

Secondary outcomes will include phase-specific EMG root mean square activity of tibialis anterior, gastrocnemius medialis, vastus lateralis and biceps femoris, as well as co-activation ratios of antagonistic muscle pairs at the ankle and knee across gait phases. These measures will quantify changes in neuromuscular control patterns associated with tDCS and their contribution to changes in gait asymmetry.

Clinical and functional measures:

Disease severity (Hoehn and Yahr stage, UPDRS motor part III) and cognitive status (Montreal Cognitive Assessment) will be analyzed as secondary outcomes and potential correlates of changes in gait asymmetry. Exploratory analyses may examine associations between changes in gait/EMG asymmetry and clinical variables to better understand which patients benefit most from the intervention.

Tamanho da Amostra no 28
Data do Primeiro Recrutamento: 03/08/2026

Países de Recrutamento		
País de Origem do Estudo	País	Nº de participantes da pesquisa
Sim	BRASIL	28

Outras Informações

Haverá uso de fontes secundárias de dados (prontuários, dados demográficos, etc)?

Sim

Detalhamento:

O grau de acometimento e o estágio evolutivo da doença de Parkinson serão verificados a partir da "unified Parkinson's disease rating scale" (UPDRS) e pela escala de Hoen Yarh respectivamente. A condição cognitiva global de cada participante será verificada de acordo com o "Montreal cognitive assessment" (MoCA) corrigido de acordo com os níveis de escolaridade. Por fim, um esquinários sobre possível efeitos adversos da aplicação da estimulação transcraniana por corrente contínua será aplicado em cada participante ao termino de cada sessão de estimulação.

Informe o número de indivíduos abordados pessoalmente, recrutados, ou que sofrerão algum tipo de intervenção neste centro de pesquisa:

28

Grupos em que serão divididos os participantes da pesquisa neste centro

ID Grupo	Nº de Indivíduos	Intervenções a serem realizadas
Grupo ETCC sham	14	os participantes irão receber a estimulação por 10 segundos
Grupo ETCC ativo	14	os participantes irão receber a estimulação por 20 minutos

O Estudo é Multicêntrico no Brasil?

Não

Propõe dispensa do TCLE?

Não

Haverá retenção de amostras para armazenamento em banco?

Não

Cronograma de Execução

Identificação da Etapa	Início (DD/MM/AAAA)	Término (DD/MM/AAAA)
Estudo 2	05/10/2026	21/12/2026
Recrutamento inicial e aplicação das escalas de caracterização da amostra	01/07/2026	31/07/2026
elaboração de relatórios e escrita de artigos	11/01/2027	31/03/2027
Estudo 1	03/08/2026	30/09/2026

Orçamento Financeiro

Identificação de Orçamento	Tipo	Valor em Reais (R\$)
nada a declarar até o presente momento	Outros	R\$ 0,00
Total em R\$		R\$ 0,00

Bibliografia:

1. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annual Review of Pathology: Mechanisms of Disease. 2011;6:193-222. 2. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery & psychiatry. 2008;79(4):368-76. 3. Rennie L, Löfgren N, Moe-Nilssen R, Opheim A, Dietrichs E, Franzén E. The reliability of gait variability measures for individuals with Parkinson's disease and healthy older adults; The effect of gait speed. Gait & Posture. 2018;62:505-9. 4. Ellis RJ, Ng YS, Zhu S, Tan DM, Anderson B, Schlaug G, et al. A validated smartphone-based assessment of gait and gait variability in Parkinson's disease. PLoS one. 2015;10(10):e0141694. 5. Galna B, Lord S, Rochester L. Is gait variability reliable in older adults and Parkinson's disease? Towards an optimal testing protocol. Gait & posture. 2013;37(4):580-5. 6. Boonstra TA, van Vugt JP, van der Kooij H, Bloem BR. Balance asymmetry in Parkinson's disease and its contribution to freezing of gait. PLoS One. 2014;9(7):e102493. 7. Plotnik M, Hausdorff JM. The role of gait rhythmicity and bilateral coordination of stepping in the pathophysiology of freezing of gait in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2008;23(S2):S444-S50. 8. Frazzitta G, Pezzoli G, Bertotti G, Maestri R. Asymmetry and freezing of gait in parkinsonian patients. Journal of Neurology. 2013;260(1):71-6. 9. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson's disease. Clinical neuropharmacology. 1989;12(2):98-105. 10. Wood B, Bilclough J, Bowron A, Walker R. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. Journal of Neurology, Neurosurgery & Psychiatry. 2002;72(6):721-5. 11. Sadeghi H, Allard P, Prince F, Labelle H. Symmetry and limb dominance in able-bodied gait: a review. Gait & posture. 2000;12(1):34-45. 12. Sadeghi H. Local or global asymmetry in gait of people without impairments. Gait & posture. 2003;17(3):197-204. 13. Yogev G, Plotnik M, Peretz C, Giladi N, Hausdorff JM. Gait asymmetry in patients with Parkinson's disease and elderly fallers: when does the bilateral coordination of gait require attention? Experimental brain research. 2007;177(3):336-46. 14. Patterson KK, Gage WH, Brooks D, Black SE, McIlroy WE. Evaluation of gait symmetry after stroke: a comparison of current methods and recommendations for standardization. Gait & posture. 2010;31(2):241-6. 15. Halim HNA, Azaman A, Manaf H, Saidin S, Zulkapri I, Yahya A, editors. Gait Asymmetry Assessment using Muscle Activity Signal: A Review of Current Methods. Journal of Physics:

Conference Series; 2019: IOP Publishing. 16. Plotnik M, Giladi N, Hausdorff JM. Bilateral coordination of walking and freezing of gait in Parkinson's disease. *European Journal of Neuroscience*. 2008;27(8):1999-2006. 17. Fasano A, Herzog J, Seifert E, Stolze H, Falk D, Reese R, et al. Modulation of gait coordination by subthalamic stimulation improves freezing of gait. *Movement Disorders*. 2011;26(5):844-51. 18. Plotnik M, Giladi N, Balash Y, Peretz C, Hausdorff JM. Is freezing of gait in Parkinson's disease related to asymmetric motor function? *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 2005;57(5):656-63. 19. Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. *Journal of the neurological sciences*. 2003;212(1-2):47-53. 20. Prokop T, Berger W, Zijlstra W, Dietz V. Adaptational and learning processes during human split-belt locomotion: interaction between central mechanisms and afferent input. *Experimental brain research*. 1995;106(3):449-56. 21. Barbieri FA, Simieli L, Orcioli-Silva D, Baptista AM, Borkowske Pestana M, Spiandor Beretta V, et al. Obstacle avoidance increases asymmetry of crossing step in individuals with Parkinson's disease and neurologically healthy individuals. *Journal of Motor Behavior*. 2018;50(1):17-25. 22. Orcioli-Silva D, Barbieri FA, Dos Santos PCR, Beretta VS, Simieli L, Vitorio R, et al. Double obstacles increase gait asymmetry during obstacle crossing in people with Parkinson's disease and healthy older adults: A pilot study. *Scientific Reports*. 2020;10(1):1-8. 23. Barbieri FA, Polastri PF, Gobbi LTB, Simieli L, Pereira VIA, Baptista AM, et al. Obstacle circumvention and eye coordination during walking to least and most affected side in people with Parkinson's disease. *Behavioural brain research*. 2018;346:105-14. 24. Takakusaki K. Functional neuroanatomy for posture and gait control. *Journal of movement disorders*. 2017;10(1):1. 25. Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*. 2008;23(S3):S548-S59. 26. Pino-Esteban A, Megía-García Á, Martín-Caro Álvarez D, Beltran-Alacreu H, Avendaño-Coy J, Gómez-Soriano J, Serrano-Muñoz D. Can Transcranial Direct Current Stimulation Enhance Functionality in Older Adults? A Systematic Review. *J Clin Med*. 2021 Jul 3;10(13):2981. 27. Rossini PM, Burke D, Chen R, Cohen L, Daskalakis Z, Di Iorio R, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an IFCN Committee. *Clinical neurophysiology*. 2015;126(6):1071-107. 28. Priori A. Brain polarization in humans: a reappraisal of an old tool for prolonged non-invasive modulation of brain excitability. *Clinical neurophysiology*. 2003;114(4):589-95. 29. Lang N, Siebner HR, Ward NS, Lee L, Nitsche MA, Paulus W, et al. How does transcranial DC stimulation of the primary motor cortex alter regional neuronal activity in the human brain? *European Journal of Neuroscience*. 2005;22(2):495-504. 30. Fregni F, Boggio PS, Santos MC, Lima M, Vieira AL, Rigonatti SP, et al. Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease. *Movement disorders*. 2006;21(10):1693-702. 31. Beretta, V. S., Orcioli-Silva, D., Zampier, V. C., Moraca, G. A. G., Pereira, M. P., Gobbi, L. T. B., & Vitorio, R.. Eight sessions of transcranial electrical stimulation for postural response in people with Parkinson's disease: A randomized trial. *Gait & Posture*. 2024; 114, 1-7. 32. Yi D, Sung Y, Yim J. Effect of Transcranial Direct Current Stimulation on Walking Speed, Functional Strength, and Balance in Older Adults: A Randomized, Double-Blind Controlled Trial. *Med Sci Monit*. 2021 Jul 30;27:e932623. 33. Wu AD, Petzinger GM, Lin CHJ, Kung M, Fisher B. Asymmetric corticomotor excitability correlations in early Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*. 2007;22(11):1587-93. 34. Kojovic M, Bologna M, Kassavetis P, Murase N, Palomar F, Berardelli A, et al. Functional reorganization of sensorimotor cortex in early Parkinson disease. *Neurology*. 2012;78(18):1441-8. 35. Li JY, Espay AJ, Gunraj CA, Pal PK, Cunic DI, Lang AE, et al. Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements. *Movement Disorders*. 2007;22(6):813-21. 36. Spagnolo F, Coppi E, Chieffo R, Straffi L, Fichera M, Nuara A, et al. Interhemispheric balance in Parkinson's disease: a transcranial magnetic stimulation study. *Brain stimulation*. 2013;6(6):892-7. 37. Latella D, Maggio MG, Maresca G, Saporoso AF, Le Cause M, Manuli A, et al. Impulse control disorders in Parkinson's disease: A systematic review on risk factors and pathophysiology. *Journal of the Neurological Sciences*. 2019;398:101-6. 38. Zaman V, Shields DC, Shams R, Drasites KP, Matzelle D, Haque A, et al. Cellular and molecular pathophysiology in the progression of Parkinson's disease. *Metabolic brain disease*. 2021;36:815-27. 39. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. *Cold Spring Harbor perspectives in medicine*. 2012;2(8):a009258. 40. Bergman H, Deuschl G. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. *Movement disorders: official journal of the Movement Disorder Society*. 2002;17(S3):S28-S40. 41. Santens P, Boon P, Van Roost D, Caemaert J. The pathophysiology of motor symptoms in Parkinson's disease. *Acta Neurologica Belgica*. 2003;103(3):129-34. 42. Takakusaki, K., Tomita, N., & Yano, M. Substrates for normal gait and pathophysiology of gait disturbances with respect to the basal ganglia dysfunction. *Journal of neurology*. 2008; 255, 19-29. 43. Whittle MW. Gait analysis. The soft tissues: Elsevier; 1993. p. 187-99. 44. Sutherland DH, Olshen R, Cooper L, Woo SL. The development of mature gait. *Jbjs*. 1980;62(3):336-53. 45. Kong K, Tomizuka M, editors. Smooth and continuous human gait phase detection based on foot pressure patterns. 2008 IEEE International Conference on Robotics and Automation; 2008: IEEE. 46. Kimmeskamp S, Hennig EM. Heel to toe motion characteristics in Parkinson patients during free walking. *Clinical biomechanics*. 2001;16(9):806-12. 47. Horak FB, Mancini M. Objective biomarkers of balance and gait for Parkinson's disease using body-worn sensors. *Movement Disorders*. 2013;28(11):1544-51. 48. Peterson D, Horak FB. Neural control of walking in people with parkinsonism. *Physiology*. 2016;31(2):95-107. 49. Rosin R, Topka H, Dichgans J. Gait initiation in Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*. 1997;12(5):682-90. 50. Mirelman A, Bonato P, Camicioli R, Ellis TD, Giladi N, Hamilton JL, et al. Gait impairments in Parkinson's disease. *The Lancet Neurology*. 2019;18(7):697-708. 51. Mihçilç L-I, Cordoç C-G, Ilçan RR, Faragó P, Hintea S, editors. CNN-based Identification of Parkinsonian Gait using Ground Reaction Forces. 2022 45th International Conference on Telecommunications and Signal Processing (TSP); 2022: IEEE. 52. Park J. Movement disorders following cerebrovascular lesion in the basal ganglia circuit. *Journal of movement disorders*. 2016;9(2):71. 53. Sian J, Gerlach M, Youdim M, Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. *Journal of neural transmission*. 1999;106:443-76. 54. Wenning GK, Odin P, Morrish P, Rehn Crona S, Widner H, Brundin P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1997;42(1):95-107. 55. Favre J, Burchiel KJ, Taha JM, Hammerstad J. Outcome of unilateral and bilateral pallidotomy for Parkinson's disease: patient assessment. *Neurosurgery*. 2000;46(2):344. 56. Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. *Movement Disorders*. 2010;25(6):710-6. 57. Wang J, Yang QX, Sun X, Vesek J, Mosher Z, Vasavada M, et al. MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson's disease. *Parkinsonism & related disorders*. 2015;21(6):590-6. 58. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. *Neurology*. 1998;50(2):318-. 59. Miller-Patterson C, Buesa R, McLaughlin N, Jones R, Akbar U, Friedman JH. Motor asymmetry over time in Parkinson's disease. *Journal of the neurological sciences*. 2018;393:14-7. 60. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. *The Lancet Neurology*. 2006;5(9):796-802. 61. Haaxma C, Helmich R, Borm G, Kappelle A, Horstink M, Bloem B. Side of symptom onset affects motor dysfunction in Parkinson's disease. *Neuroscience*. 2010;170(4):1282-5. 62. Riederer P, Sian-Hülsmann J. The significance of neuronal lateralisation in Parkinson's disease. *Journal of Neural Transmission*. 2012;119:953-62. 63. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *Journal of neurology, neurosurgery & psychiatry*. 1992;55(3):181-4. 64. Suchowersky O, Reich S, Perlmuter J, Zesiewicz T, Gronseth G, Weiner W. Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review)[RETIRED]. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2006;66(7):968-75. 65. Thenganatt MA, Louis ED. Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. *Expert review of neurotherapeutics*. 2012;12(6):687-96. 66. Hipp G. Das Luxemburger Parkinson-Kohortenprogramm: Neue Strategien für eine umfassende Studie zur Erfassung von Biodaten und klinischen Daten. *Basal Ganglia*.

2015;1(5):XVI. 67. Uitti RJ, Baba Y, Whaley N, Wszolek ZK, Putzke J. Parkinson disease: handedness predicts asymmetry. *Neurology*. 2005;64(11):1925-30. 68. Louis ED, Levy G, Côte LJ, Mejia H, Fahn S, Marder K. Clinical correlates of action tremor in Parkinson disease. *Archives of neurology*. 2001;58(10):1630-4. 69. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? *Movement disorders: official journal of the Movement Disorder Society*. 2003;18(S7):S43-S51. 70. Delwaide P, Pepin J-L, de Noordhout AM. The audiospinal reaction in parkinsonian patients reflects functional changes in reticular nuclei. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1993;33(1):63-9. 71. Pahapill PA, Lozano AM. The pedunculo-pontine nucleus and Parkinson's disease. *Brain*. 2000;123(9):1767-83. 72. Su W, Li K, Li C-M, Ma X-X, Zhao H, Chen M, et al. Motor symptom lateralization influences cortico-striatal functional connectivity in Parkinson's disease. *Frontiers in Neurology*. 2021;12:619631. 73. Drenth LK, Albert ML, Volicer L, Langlais PJ, Marquis J, Kaplan E. Parkinson's disease: The possible relationship of laterality to dementia and neurochemical findings. *Archives of Neurology*. 1984;41(9):935-41. 74. Winter DA. Biomechanics and motor control of human gait: normal, elderly and pathological. 1991. 75. Winter DA, Eng P. Kinetics: our window into the goals and strategies of the central nervous system. *Behavioural brain research*. 1995;67(2):111-20. 76. Hamacher D, Herold F, Wiegel P, Hamacher D, Schega L. Brain activity during walking: a systematic review. *Neuroscience & Biobehavioral Reviews*. 2015;57:310-27. 77. Mak MK, Wong-Yu IS. Exercise for Parkinson's disease. *International review of neurobiology*. 2019;147:1-44. 78. Ujjan JA, Morani W, Memon N, Mohanasundaram S, Nuhmani S, Singh BK. Force platform-based intervention program for individuals suffering with neurodegenerative diseases like parkinson. *Computational and Mathematical Methods in Medicine*. 2022;2022. 79. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends in neurosciences*. 1990;13(7):266-71. 80. DeLong MR. Primate models of movement disorders of basal ganglia origin. *Trends in neurosciences*. 1990;13(7):281-5. 81. Rascol O, Sabatini U, Chollet F, Celsis P, Montastruc J-L, Marc-Vergnes J-P, et al. Supplementary and primary sensory motor area activity in Parkinson's disease: regional cerebral blood flow changes during finger movements and effects of apomorphine. *Archives of Neurology*. 1992;49(2):144-8. 82. Playford E, Jenkins I, Passingham R, Nutt J, Frackowiak R, Brooks D. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1992;32(2):151-61. 83. Samuel M, Ceballos-Baumann A, Turjanski N, Boecker H, Grosse P, Linazasoro G, et al. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements: an H2 (15) O PET study. *Brain: a journal of neurology*. 1997;120(8):1301-13. 84. Hanakawa T, Fukuyama H, Katsumi Y, Honda M, Shibasaki H. Enhanced lateral premotor activity during paradoxical gait in Parkinson's disease. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1999;45(3):329-36. 85. Roemmich RT, Nocera JR, Stegemöller EL, Hassan A, Okun MS, Hass CJ. Locomotor adaptation and locomotor adaptive learning in Parkinson's disease and normal aging. *Clinical Neurophysiology*. 2014;125(2):313-9. 86. Fling BW, Curtze C, Horak FB. Gait asymmetry in people with Parkinson's disease is linked to reduced integrity of callosal sensorimotor regions. *Frontiers in neurology*. 2018;9:215. 87. Claassen DO, McDonnell KE, Donahue M, Rawal S, Wylie SA, Neimat JS, et al. Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. *Brain and behavior*. 2016;6(12):e00573. 88. Plotnik M, Giladi N, Hausdorff JM. Bilateral coordination of gait and Parkinson's disease: the effects of dual tasking. *Journal of Neurology, Neurosurgery & Psychiatry*. 2009;80(3):347. 89. Mirelman A, Bernadé Elazari H, Thaler A, Giladi Yacobi E, Gurevich T, Ganaé Weisz M, et al. Arm swing as a potential new prodromal marker of Parkinson's disease. *Movement Disorders*. 2016;31(10):1527-34. 90. Wang H-C, Hsu J-L, Leemans A. Diffusion Tensor Imaging of Vascular Parkinsonism. *VASCULAR*. 2012. 91. Dembek TA, Barbe MT, Åström M, Hoefels M, Visser-Vandewalle V, Fink GR, et al. Probabilistic mapping of deep brain stimulation effects in essential tremor. *NeuroImage: Clinical*. 2017;13:164-73. 92. Fling BW, Kwak Y, Peltier SJ, Seidler RD. Differential relationships between transcallosal structural and functional connectivity in young and older adults. *Neurobiology of aging*. 2012;33(10):2521-6. 93. Gooijers J, Swinnen SP. Interactions between brain structure and behavior: the corpus callosum and bimanual coordination. *Neuroscience & Biobehavioral Reviews*. 2014;43:1-19. 94. Sohn YH, Jung HY, Kaelin-Lang A, Hallett M. Excitability of the ipsilateral motor cortex during phasic voluntary hand movement. *Experimental brain research*. 2003;148(2):176-85. 95. Stinear CM, Byblow WD. Role of intracortical inhibition in selective hand muscle activation. *Journal of neurophysiology*. 2003;89(4):2014-20. 96. Debaere F, Swinnen SP, Béatse E, Sunaert S, Van Hecke P, Duysens J. Brain areas involved in interlimb coordination: a distributed network. *Neuroimage*. 2001;14(5):947-58. 97. Thomas GEC, Leyland LA, Schrag A-E, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2020;91(4):418. 98. Chung M, Park YS, Kim JS, Kim YJ, Ma HI, Jang SJ, et al. Correlating Parkinson's disease motor symptoms with three-dimensional [18F]FP-CIT PET. *Japanese Journal of Radiology*. 2015;33(10):609-18. 99. Ricciardi L, Ricciardi D, Lena F, Plotnik M, Petracca M, Barricella S, et al. Working on asymmetry in Parkinson's disease: randomized, controlled pilot study. *Neurological Sciences*. 2015;36(8):1337-43. 100. Son M, Han SH, Lyoo CH, Lim JA, Jeon J, Hong K-B, et al. The effect of levodopa on bilateral coordination and gait asymmetry in Parkinson's disease using inertial sensor. *npj Parkinson's Disease*. 2021;7(1):42. 101. Blosser JA, Podolsky E, Lee D. L-DOPA-Induced Dyskinesia in a Genetic *Drosophila* Model of Parkinson's Disease. *Experimental Neurobiology*. 2020;29(4):273. 102. Latash ML. Neurophysiological basis of movement: Human Kinetics; 2008. 103. Okun MS. Deep-brain stimulation for Parkinson's disease. *New England Journal of Medicine*. 2012;367(16):1529-38. 104. Benabid AL. Deep brain stimulation for Parkinson's disease. *Current opinion in neurobiology*. 2003;13(6):696-706. 105. Zarzycki MZ, Domitry I. Stimulation-induced side effects after deep brain stimulation: a systematic review. *Acta Neuropsychiatrica*. 2020;32(2):57-64. 106. Cursiol JA, Dos Santos PCR, Beretta VS, Orcioli-Silva D, Simieli L, Schlenstedt C, Coelho DB, Barbieri FA. Rhythmic auditory cues improve gait asymmetry during unobstructed walking in people with Parkinson's disease but have no effect on obstacle avoidance - AsymmGait-Parkinson study. *Front Aging Neurosci*. 2025 Feb 27;17:1455432. 107. Beretta, V. S., Santos, P. C. R., Orcioli-Silva, D., Zampier, V. C., Vitorio, R., & Gobbi, L. T. B. Transcranial direct current stimulation for balance rehabilitation in neurological disorders: A systematic review and meta-analysis. *Ageing Research Reviews*. 2022; 81, 101736. 108. Broeder, S., Nackaerts, E., Heremans, E., Vervoort, G., Meesen, R., Verheyden, G., & Nieuwboer, A. Transcranial direct current stimulation in Parkinson's disease: Neurophysiological mechanisms and behavioral effects. *Neurosci Biobehav Rev* 2015; 105:117-57. 109. Zampier, V. C. The effect of transcranial direct current stimulation and physical exercise on interlimb coordination during walking in people with Parkinson's disease. 2024. 110. van der Kolk NM, King LA. Effects of exercise on mobility in people with Parkinson's disease. *Movement Disorders*. 2013;28(11):1587-96. 111. Pavlova E, Semenov R, Guekht A. Effect of tDCS on fine motor control of patients in subacute and chronic post-stroke stages. *Journal of motor behavior*. 2020;52(4):383-95. 112. Seuthe J, D'cruz N, Ginis P, Becktepe JS, Weisser B, Nieuwboer A, et al. The effect of one session split-belt treadmill training on gait adaptation in people with Parkinson's disease and freezing of gait. *Neurorehabilitation and Neural Repair*. 2020;34(10):954-63. 113. Farrell III JW, Merkas J, Pilutti LA. The effect of exercise training on gait, balance, and physical fitness asymmetries in persons with chronic neurological conditions: a systematic review of randomized controlled trials. *Frontiers in physiology*. 2020;11:585765. 114. Panero E, Digo E, Dimanico U, Artusi CA, Zibetti M, Gastaldi L, editors. Effect of deep brain stimulation frequency on gait symmetry, smoothness and variability using IMU. 2021 IEEE International Symposium on Medical Measurements and Applications (Memea); 2021: IEEE. 115. Dobbs B, Pawlak N, Biagioni M, Agarwal S, Shaw M, Pilloni G, et al. Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson's disease. *Journal of neuroengineering and rehabilitation*. 2018;15(1):1-8. 116. Nitsche MA, Liebetanz D, Tergau F, Paulus W. Modulation of cortical excitability by transcranial direct current stimulation. *Der Nervenarzt*. 2002;73(4):332-5. 117. Ghabra MB, Hallett M, Wassermann EM. Simultaneous repetitive transcranial magnetic stimulation does not speed fine movement in PD. *Neurology*. 1999;52(4):768-. 118. Siebner HR, Mentschel C, Auer C, Conrad B. Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson's disease. *NeuroReport*. 1999;10

(3). 119. Kaski D, Dominguez R, Allum J, Islam A, Bronstein A. Combining physical training with transcranial direct current stimulation to improve gait in Parkinson's disease: a pilot randomized controlled study. *Clinical rehabilitation*. 2014;28(11):1115-24. 120. Benninger DH, Lomarev M, Lopez G, Wassermann EM, Li X, Considine E, et al. Transcranial direct current stimulation for the treatment of Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010;81(10):1105-11. 121. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *Journal of Neuroscience*. 2001;21(15):RC157-RC. 122. Whitton PS. Glutamatergic control over brain dopamine release in vivo and in vitro. *Neuroscience & Biobehavioral Reviews*. 1997;21(4):481-8. 123. Lu C, Wei Y, Hu R, Wang Y, Li K, Li X. Transcranial direct current stimulation ameliorates behavioral deficits and reduces oxidative stress in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced mouse model of Parkinson's disease. *Neuromodulation: Technology at the Neural Interface*. 2015;18(6):442-7. 124. Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. *The Journal of physiology*. 2000;527(Pt 3):633. 125. Nonnekes J, Arroggi A, Munneke MA, van Asseldonk EH, Oude Nijhuis LB, Geurts AC, et al. Subcortical structures in humans can be facilitated by transcranial direct current stimulation. *PLoS one*. 2014;9(9):e107731. 126. Radman T, Ramos RL, Brumberg JC, Bikson M. Role of cortical cell type and morphology in subthreshold and suprathreshold uniform electric field stimulation in vitro. *Brain stimulation*. 2009;2(4):215-28. e3. 127. Parasuraman R, McKinley RA. Using noninvasive brain stimulation to accelerate learning and enhance human performance. *Human factors*. 2014;56(5):816-24. 128. Tanaka T, Takano Y, Tanaka S, Hironaka N, Kobayashi K, Hanakawa T, et al. Transcranial direct-current stimulation increases extracellular dopamine levels in the rat striatum. *Frontiers in systems neuroscience*. 2013;7:6. 129. Cosentino G, Valentino F, Todisco M, Alfonsi E, Davi R, Savettieri G, et al. Effects of more-affected vs. less-affected motor cortex tDCS in Parkinson's disease. *Frontiers in human neuroscience*. 2017;11:309. 130. Agostino R, Currà A, Soldati G, Dinapoli L, Chiacchiari L, Modugno N, et al. Prolonged practice is of scarce benefit in improving motor performance in Parkinson's disease. *Movement Disorders: Official Journal of the Movement Disorder Society*. 2004;19(11):1285-93. 131. Diedrichsen J, Hashambhoy Y, Rane T, Shadmehr R. Neural correlates of reach errors. *Journal of Neuroscience*. 2005;25(43):9919-31. 132. Doyon J, Bellec P, Amis R, Penhune V, Monchi O, Carrier J, et al. Contributions of the basal ganglia and functionally related brain structures to motor learning. *Behavioural brain research*. 2009;199(1):61-75. 133. Wu T, Hallett M. A functional MRI study of automatic movements in patients with Parkinson's disease. *Brain*. 2005;128(10):2250-9. 134. Ferrucci R, Mameli F, Ruggiero F, Priori A. Transcranial direct current stimulation as treatment for Parkinson's disease and other movement disorders. *Basal Ganglia*. 2016;6(1):53-61. 135. Robinson AG, Dennett AM, Snowden DA. Treadmill training may be an effective form of task-specific training for improving mobility in people with Parkinson's disease and multiple sclerosis: a systematic review and meta-analysis. *Physiotherapy*. 2019;105(2):174-86. 136. Briennes LA, Emerson MN. Effects of resistance training for people with Parkinson's disease: a systematic review. *Journal of the American Medical Directors Association*. 2013;14(4):236-41. 137. Costa-Ribeiro A, Maux A, Bosford T, Aoki Y, Castro R, Baltar A, et al. Transcranial direct current stimulation associated with gait training in Parkinson's disease: A pilot randomized clinical trial. *Developmental Neurorehabilitation*. 2017;20(3):121-8. 138. Kaski D, Allum JH, Bronstein AM, Dominguez RO. Applying anodal tDCS during tango dancing in a patient with Parkinson's disease. *Neuroscience Letters*. 2014;568:39-43. 139. Pol F, Salehinejad MA, Baharlouei H, Nitsche MA. The effects of transcranial direct current stimulation on gait in patients with Parkinson's disease: a systematic review. *Translational Neurodegeneration*. 2021;10(1):22. 140. Lee HK, Ahn SJ, Shin YM, Kang N, Cauraugh JH. Does transcranial direct current stimulation improve functional locomotion in people with Parkinson's disease? A systematic review and meta-analysis. *Journal of Neuroengineering and rehabilitation*. 2019;16(1):1-13. 141. Conceição NR, Gobbi LTB, Nóbrega-Sousa P, Orzioli-Silva D, Beretta VS, Lirani-Silva E, et al. Aerobic exercise combined with transcranial direct current stimulation over the prefrontal cortex in Parkinson disease: effects on cortical activity, gait, and cognition. *Neurorehabilitation and neural repair*. 2021;35(8):717-28. 142. Mak KY, Yu L, editors. Effects of transcranial direct current stimulation on dual-task gait performance in patients with Parkinson's disease. *International Congress of Clinical Neurophysiology*; 2014. 143. Lattari E, Costa SS, Campos C, de Oliveira AJ, Machado S, Neto GAM. Can transcranial direct current stimulation on the dorsolateral prefrontal cortex improves balance and functional mobility in Parkinson's disease? *Neuroscience letters*. 2017;636:165-9. 144. Manenti R, Brambilla M, Rosini S, Orizio I, Ferrari C, Borroni B, et al. Time up and go task performance improves after transcranial direct current stimulation in patient affected by Parkinson's disease. *Neuroscience letters*. 2014;580:74-7. 145. Wong P, Yang Y, Huang S, Fuh J, Chiang H, & Wang R. Transcranial Direct Current Stimulation on Different Targets to Modulate Cortical Activity and Dual-Task Walking in Individuals With Parkinson's Disease: A Double Blinded Randomized Controlled Trial. *Frontiers in Aging Neuroscience*. 2022; 14, 807151. 146. Barbieri FA, Faria MH, Simieli L, Penedo T, Kalva Filho CA, Beretta VS. Gait velocity and stability are correlated to muscle and bone mass loss in people with Parkinson's disease: a preliminary study. *Brazilian Journal of Motor Behavior*. 2022;16(5):362-71. 147. Herzog, W. A. L. T. E. R., Nigg, B. M., Read, L. J., & Olsson, E. W. A. (). Asymmetries in ground reaction force patterns in normal human gait. *Med Sci Sports Exerc*. 1989, 21, 110-114. 148. Fahn S, Elton R. UPDRS program members. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease. 1987;2:153-63. 149. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*. 2005;53(4):695-9. 150. Swank, C., Mehta, J., & Criminger, C. Transcranial direct current stimulation lessens dual task cost in people with Parkinson's disease. *Neuroscience letters*. 2016; 626, 1-5. 151. Bueno, M. E. B., do Nascimento Neto, L. I., Terra, M. B., Barboza, N. M., Okano, A. H., & Smaili, S. M. Effectiveness of acute transcranial direct current stimulation on non-motor and motor symptoms in Parkinson's disease. *Neuroscience letters*. 2019; 696, 46-5. 152. Mishra Rk, Thrasher AT. Transcranial direct current stimulation of dorsolateral prefrontal cortex improves dual-task gait performance in patients with Parkinson's disease: A double blind, sham-controlled study. *Gait & Posture*. 2021;84:11-6. 153. Hadoush H, Al-Sharman A, Khalil H, Banihani SA, Al-Jarrah M. Sleep quality, depression, and quality of life after bilateral anodal transcranial direct current stimulation in patients with Parkinson's disease. *Medical science monitor basic research*. 2018;24:198. 154. Yotnuengnit P, Bhidayasir R, Donkhan R, Chalauysrimuang J, & Piravej K. Effects of transcranial direct current stimulation plus physical therapy on gait in patients with Parkinson disease: a randomized controlled trial. *American journal of physical medicine & rehabilitation*. 2018;97(1), 7-15. 155. Benninger, D. H., Lomarev, M., Lopez, G., Wassermann, E. M., Li, X., Considine, E., & Hallett, M. (). Transcranial direct current stimulation for the treatment of Parkinson's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010;81(10), 1105-1111. 156. Miranda PC, Lomarev M, Hallett M. Modeling the current distribution during transcranial direct current stimulation. *Clinical neurophysiology*. 2006;117(7):1623-9. 157. Manenti R, Brambilla M, Benussi A, Rosini S, Cobelli C, Ferrari C, et al. Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy. *Movement Disorders*. 2016;31(5):715-24. 158. King L, Horak F. On the mini-BESTest: scoring and the reporting of total scores. *Physical therapy*. 2013;93(4):571-5. 159. de Moraes Filho AV, Chaves SN, Martins WR, Tolentino GP, Homem RdCPP, de Farias GL, et al. Progressive resistance training improves bradykinesia, motor symptoms and functional performance in patients with Parkinson's disease. *Clinical Interventions in Aging*. 2020;15:87. 160. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal statistical society: series B (Methodological)*. 1995;57(1):289-300.

TCLE / Termos de Assentimento / Justificativa de Ausência	TCLE_posdoc_zampier.docx
Projeto Detalhado / Brochura Investigador	projeto_posdoc_R1_V2.docx
Folha de Rosto	folha_de_rosto_ass_zampier.pdf
Cronograma	cronograma_zampier.docx

Finalizar

Manter sigilo da integra do projeto de pesquisa: Sim

Prazo: Até a publicação dos resultados